Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

During a routine health maintenance examination, a physician evaluates a patient with poorly controlled type 2 diabetes mellitus and new-onset eruptive xanthomas on the extensor surfaces. Fasting laboratory results reveal a serum triglyceride concentration of 1,340 mg/dL1,340 \text{ mg/dL}. The patient is currently managed with metformin monotherapy and lacks any history of atherosclerotic cardiovascular disease.

Please arrange the following clinical actions in the correct chronological sequence for the management and monitoring of this patient's condition over time.

  1. 1Prescribe fenofibrate to rapidly reduce the immediate risk of acute pancreatitis.
  2. 2Recheck a fasting lipid panel in 4 to 8 weeks to confirm the triglyceride concentration has decreased below 500 mg/dL500 \text{ mg/dL}.
  3. 3Initiate statin therapy for primary prevention of atherosclerotic cardiovascular disease.
  4. 4Assess for new-onset muscle aches and monitor hepatic transaminases following the initiation of combination therapy.

Answer

The correct chronological sequence is to first prescribe fenofibrate to prevent pancreatitis, then recheck the lipid panel in 4 to 8 weeks, subsequently initiate statin therapy once triglycerides are <500 mg/dL<500 \text{ mg/dL}, and finally monitor for adverse effects of the combination therapy.
The management of severe hypertriglyceridemia (≥1,000 mg/dL\ge 1,000 \text{ mg/dL}) follows a strict sequence driven by competing clinical risks. The immediate danger is acute pancreatitis, dictating that fibrate therapy (e.g., fenofibrate) must be initiated first. Once the patient begins the fibrate, the physician must evaluate the therapeutic response by rechecking a fasting lipid panel in 4 to 8 weeks. When the triglyceride level safely drops below 500 mg/dL500 \text{ mg/dL}, the acute threat of pancreatitis is resolved. At this point, the patient's long-term risk of atherosclerotic cardiovascular disease (ASCVD) takes precedence. Because this patient has diabetes, a statin is strongly indicated for primary prevention. Finally, because the patient is now on combination therapy (statin plus fibrate), they are at an elevated risk for myopathy and hepatic toxicity, necessitating ongoing clinical and laboratory monitoring.

Step-by-Step Solution

1
Identify the immediate clinical threat.
The triglyceride level of 1,340 mg/dL1,340 \text{ mg/dL} places the patient at high imminent risk for acute pancreatitis.
Triglyceride levels above 500−1,000 mg/dL500-1,000 \text{ mg/dL} require immediate fibrate therapy rather than statins to prevent pancreatic inflammation.
2
Evaluate the initial treatment response.
A follow-up lipid panel is ordered 4 to 8 weeks after starting fenofibrate.
Monitoring ensures the medication is effectively lowering triglycerides below the critical 500 mg/dL500 \text{ mg/dL} threshold, establishing safety.
3
Address long-term cardiovascular risk.
Statin therapy is initiated.
Once triglycerides are <500 mg/dL<500 \text{ mg/dL}, the primary goal shifts to atherosclerotic cardiovascular disease (ASCVD) prevention, indicated for diabetic patients.
4
Monitor for adverse effects of combination therapy.
The patient is assessed for myopathy and transaminitis.
The combination of a fibrate and a statin increases the risk of muscle toxicity and liver injury, requiring careful post-initiation surveillance.

Key Concept

In patients with severe hypertriglyceridemia (≥500−1,000 mg/dL\ge 500-1,000 \text{ mg/dL}), the initial focus is preventing acute pancreatitis with fibrates; once triglycerides are successfully monitored and confirmed to be <500 mg/dL<500 \text{ mg/dL}, the focus shifts to ASCVD risk reduction with statins, followed by clinical evaluation for combined toxicity.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic